Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
| Revenue (TTM) | 158,000 |
| Gross Profit (TTM) | $-278.65M |
| EBITDA | $-322.43M |
| Operating Margin | -366468.00% |
| Return on Equity | -43.90% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.10 |
| Price-to-Book | 3.68 |
| Price-to-Sales (TTM) | 15457.40 |
| EV/Revenue | 12149.54 |
| EV/EBITDA | -17.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.00% |
| Shares Outstanding | $78.53M |
| Float | $73.02M |
| % Insiders | 0.27% |
| % Institutions | 110.27% |
Volatility is currently expanding
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.
Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in extended trading.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLDX and any ticker you trade — then tracks every position and per-strategy win rate.
